So, for example, we've been working with a bunch of our collaborators on being able to create patches that have very, very tiny needles that you wouldn't even be able to feel and through these tiny needles, you can actually deliver drugs, or be able to actually extract solutions, and be able to sample what's inside an individual, you know, potentially even in real time, and one of the things that we're doing is that we're creating these arrays of micro needles to not only deliver compounds like vaccines in a way that you can just apply yourself, but also be able to integrate these platforms with wearables and sensors and electronic sensors to be able to, in real time, monitor what's happening inside individuals. There are very few approaches to solve them. And that has generated a lot more interest in working with us. That's right. You get the opportunity to publish but then also on the founding of one of the miracles in startups which became a major enterprise. He has also pioneered various high-performance biomaterials that can respond to each patient's needs. So, I helped do some target acquisition analysis for being able to purchase a company to get into the HLA space and the transplant spaceThey are one of the strongest companies in HLA now as well, and that company's called CareDx. So, one of the things that I think it's really interesting is that the technology, again, is converging. But to do it, it takes a highly interdisciplinary approach. He wanted it geographically close to the university; we are now across the street from UCLA. And, there's lots of opportunities, I think, to accelerate working together. Now, that came out. Terasaki - University of California, Los Angeles Really to benefit of the good graces that came with his success at UCLA. I delve deeper in the science with the interviews of Ali and Maurizio though the Maurizio interview has a scaling and commercialization lens. Either use these micro needles in some sort of a sensing device, to be able to try to measure certain biomarkers in the body, or to use these micro needles as an alternative to an injection. Okay, for whatever disease I have, but that's not really it. And, so today, I get to design, not the science part, but I get to design how we take the science into that innovation ecosystem that we're trying to build. Let's explore that a little bit further. 1018 Westwood Blvd . Terasaki Institute for Biomedical Innovation - Headquarter Locations I think there's a lot of other impacts that we're making. Right now, again, pharma still uses that same kind of platforms and technologies that they've developed 50 years ago, to do their drug development and drug discovery process. The latest is to be able to kind of go in with a catheter through the blood vessels and maybe try to deploy a catheter, like a coil or something like that in those spaces; we fundamentally think that you can actually do a lot more. I have two. The Terasaki Institute for Biomedical Innovation is an independent non-profit organization and uses an integrative approach to innovate personalized health. Biomaterials also allow you to create constructs, like moving away from injections into, say micro needles. Terasaki Institute for Biomedical Innovation, Los Angeles, CA, 90064 USA. And it's unique the leading researchers are doing in this entire journey; your capability to bring in the right partners, because you have a relationship network globally. >, Ali Khademhosseini | AIChE You're growing cells, right? He was in a financial position to be able to start a Foundation Laboratory, which he did. We discuss engagements with institutions, corporations, and incubation of startups.>. And so you can study, for example, metabolic factors, and toxicity in the liver, while you are also looking at cardiotoxicity, and a target that may be for cardiovascular disease. Division of Nanobiotechnology, Department of Protein Science, Science for Life Laboratory, KTH Royal Institute of Technology, Solna, 17165 Sweden. He simultaneously managed the Global Good Fund, the research programs of the Intellectual Ventures Laboratory and the Institute for Disease Modeling. That turnaround to getting real world application is much less, whereas when you have cells and things you really have long regulatory approval. That just changed my perception of what's possible, what a single individual can do, how thinking big and aiming bigger; really important than how small questions take as much time to solve as big questions, but the impact is ultimately very different. Terasaki Institute Top Biomedical Innovations Transforming The - Forbes What are inflection points that guided your journey? But no one has had an effective way to collect it. One of the areas that he's focusing on, which happens to leave a very big footprint on the planetary health situation is with agriculture. Paul Terasaki - Wikipedia If you think about the ecosystem of biomedical innovation, and you think about the complexities that a lot of companies face, to license out of universities and dealing with the patchwork and complexities of IPs, as well creating structures that allow those companies to take risk on new technologies, without necessarily getting into a quagmire of relationship. But to answer your initial question, as I exited, Global Good, and the Gates ecosystem, I was looking for a place that could apply the learned lessons of that sort of translational innovation. I haven't really talked about that integration much. This became the flagship of the transplant diagnostic industry. The unscripted dialogue is with Bill Barrable, CEO, and Arushi Raina, Director of Commercialization, for the non-profit Praxis Spinal Cord Institute. We're in constant growth mode. So, one of the things we know with our current ability to really make small tissue with microscale resolution, being able to put the right cells in the right place, and create vasculature and be able to control that we can actually do the kind of experiments that you can never do in an animal model. That being said, I was still at One Lambda till about 2014. That's a very quick encapsulation of what's happened to me in the last couple of years in here at the Institute. So, part of the vision here is if you had physiological models that truly mimic the performance of the human organ or tissue, or system of organs, then you can use them as a real tool, with potentially much higher efficiency than an animal model for drug discovery. He was the Founding Director of the Center for Minimally Invasive Therapeutics at UCLA. Bill from his prior work as CEO of BC Transplant, is intimately familiar with and utilized the pioneering work and leadership of Dr. Paul Terasaki and Arushi speaks of the utility of the solutions offered by the present day Terasaki Institute (TIBI) in SCI. You're so entire model oriented; it's the entire ecosystem and system wide. Your ideas have to be fundable; you need to be able to get lots of great science performed and published in really high-quality journals. We definitely have a few different projects that are, I think, are really exciting. We are set up to do that. Whereas at the Institute , we're much smaller, but at the same time, we're much more careful about what kind of questions we want to answer. $123,130 / yr. Postdoctoral Researcher salaries - 5 salaries reported. Dr. Terasaki established the kidney transplant registry, which would eventually become the United Network for Organ Sharing registry. Highlights Active Tech Count 21 Monthly Visits 7,332 Monthly Visits Growth -62.09% About Terasaki Institute is actively using 21 technologies for its website, according to BuiltWith. For example, we have cardiac models, where the organs on a chip actually begins to pulsate, the way the real heart does, and we're now working on, for example, neural models where we have brains on a chip, and more importantly, we're able to start building disease on a chip. He serves on the Leadership Board of the University of Washington Department of Global Health and the Advisory Board of the UCLA Ronald Reagan Medical Center; from time to time an advisor to the US Government, the EU and multilateral organizations such as WHO and UNICEF in matters of innovation and population health. He started looking at all his data and trying to correlate cancer outcome with the HLA data that he had established, or that he was looking at. Here in Los Angeles; I spent about 16 years in Boston. 05 May, 2023, 15:44 ET. Find The Paul I. Terasaki Foundation Salaries by Job Title Terasaki Institute Holds Grand Opening Celebration at New Research Center And it's really tedious. This building should go online later this year. Aging is a mystery where scientists are gaining a better understanding of factors such as: -epigenetic changes increasing as we age via DNA methylation where chemical markers modify the function of genes; -telomeres at the ends of our cells DNA which shorten each time the cell divides; -cell senescence where cells stop dividing, are arrested in function, and accumulate with aging; -blood from young mice linked to regeneration in older mice; -added tools such as reverse CRISPR genetic manipulation; optogenetics to control cell activity with light; -proteins found in brain cells such as hypocretin attracting attention in sleep research and molecules such as microRNS-137 helping regulating hypocretin; -plasmalogens decreasing as we age; halting this decrease and supplementing thus increasing plasmalogens (do sea squirts hold a key? Aim Big. Terasaki Institute for Biomedical Innovation (TIBI) | LinkedIn And they actually have done clinical trials and have demonstrated that this works and how now have a company that recently raised its series A to be able to translate these kinds of technologies into a real-world application. Personalized nutrition; come up with alternatives for your nutrition. I just thought he might need my help in terms of some of the commercial aspects of the Institute, but quickly realized that he was really trying to groom his successor. And those micro needles can be smart. Definitely. Cells treated with Yamanaka factors, erases marks on the epigenome, losing their identity thus the reversal to the embryonic state (stem cell). And all of this, again, will involve a lot of data collection, machine learning AI algorithms that can actually make these kinds of interactions happen. The work in biomedical innovation is further supported by tremendous advances in AI/ML and Robotics. in the QS World University Rankings by Subject 2020. We've been in constant hiring mode for the last 24 months. Being able to create skin models that can be used for testing, whether you know, a specific cosmetic is going to be having issues with the skin, etc. Let's see how we can work together. I am an undergraduate that was doing research work and being able to publish. He wanted this institute to have an affiliation with UCLA. I summarize added areas such as in the science of biomedical innovation and commercialization. All Rights Reserved. And those are, I think, super exciting and frankly, are going to be the future, of many devices. One of the amazing things about the Institute is it has the endowment, so we can actually use the endowment for initiatives that we want to push forward. And this is, of course, a huge problem for pharma industry and lots of other kind of areas. These could be small startups that exists elsewhere or have spun out of the Institute, or large conglomerates that are interested in particular areas we have a lot more leeway. There's a lot of opportunity in those concepts. His work continues to be the foundation for the next generation of robotics. That's the end using cells and materials to, and techniques like 3D printing to actually create living tissues. And you have a model where you can scale and commercialize it means that you can have huge impact. When we look at a lot of different things, we really think about how does nature do it? And I think, to be clear, I'm not suggesting that the Terasaki Institute can literally do the scaling and all those other steps that you're talking about. As outlined in their recent publication in Cell Stem Cell, the team developed a droplet-based microfluidic technology to produce micro-organospheres (MOS) from cancer patient biopsies within an hour. To do this within the Gates ecosystem; we got to experiment with how do you affect the sort of translational work? And that's language that should be welcomed to anybody in your audience, who is looking to essentially input into the product pipeline. That's over the past two years. Our Vision: The Terasaki Institute for Biomedical Innovation envisions a world where personalized medicine is available to all. I wanted to stay in the field. Our Vision: The Terasaki Institute for Biomedical Innovation envisions a world where personalized medicine is available to all. In collaboration with leading physicians, scientists, and the biotechnology/pharmaceutical industry, they aim to solve the major problems . I had been a tissue engineer for a long timecells from cow and fish and other things, and be able to grow those cells in things that kind of look like beer brewing factories, these are bio reactors in which you have cells, and you can grow the cells and then afterwards, collect the cells and process them into meats of different sorts And I think it's one of those really game changing opportunities that we have as humanity right now. I just had this tunnel vision of looking at it from an immunologist aspect. When the drug sensitivity results were compared against actual clinical treatment outcomes, there was almost perfect correlation. Every person is unique with individual challenges to optimal health, from genetic predisposition to disease to . We like to think about the technologies that we're developing as being platforms. Why don't we think about addressing that problem in that way? I've had one boss my entire life, and that was Paul Terasaki. It's just a blessing that I come back now into research, at this phase of my career, and I'm working with a bunch of scary smart scientists. The Terasaki Institute for Biomedical Innovation is an independent non-profit organization and uses an integrative approach to innovate personalized health. You know, it's interesting. You have effective solutions. He's always working on possible collaboration with industry. In addition to wanting to continue his work and research, he had always wanted to delve into looking at the intersection of cancer and transplantation. Dr. Terasaki has many notable contributions to the field of organ transplant, such as the development of the microcytotoxicity test in 1964, which by 1970, became the international standard. So, my key message is, don't think that everything good has been invented. And then I get to this idea, because I work in science communities as well. So, to me, the reason why personalized medicine is important, is because as disease gets more complex, we're going to have to get very targeted in the delivery, in what our drugs and devices do in order to be effectivewhen you think about cancer therapies, for example, it's all about targeting, and it's all about stage of the cancer, and it's all about the heterogeneity of the cancer, as it moves across its phases, and its patients. It can be injected into the body to treat wounds on the heart or treat wounds on the liver. He was the Founding Director of the Center for Minimally Invasive Therapeutics at UCLA. Unfortunately, he passed in 2016; he wasn't here to see the opening, which was later in 2016. From 2014 until 2020, he was the executive vice president for Global Good and Research at Intellectual Ventures (IV) where he oversaw collaboration with Bill Gates to invent and deploy technology to address some of humanity's most daunting challenges. I could see a lot of possibilities, even integrating this with the metaverse? Ali Khademhosseini is the CEO of the Terasaki Institute for Biomedical Innovation. He had retired from UCLA in 1999. Are there some other areas that you're going to hope to achieve by let's say, 2025? So be able to sense disease, in real time, are the kinds of things that we're interested in doing in the future. So, for example, if you put these materials inside the blood vessels of tumors, then they can actually release drugs and be able to destroy the tumor; if you put them in an area like an aneurysm, then they not only provide mechanical strength to prevent that aneurysm but they also can induce regeneration of the blood vessel and healing. He's one of those individuals that reminds me of Paul Terasaki. They are all very passionate about what they do. Los Angeles, California, 90024, United States They can react to physical conditions, like materials that become hard under certain conditions, but they're liquid when you first inject them so they can travel the body and react to specific positions and for example embolize, a vessel without the need for surgery. He was one of those types of individuals, could always think outside the box, looking at things from a 30,000-foot level and then be able to zero in. And there were a number of lessons that maybe we'll talk about in a minute. Terasaki Institute for Biomedical Innovation Headquarter Location. So being able to have cells in the body work with the materials to provide a specific activity, like go after tumor cells, etc. And I guess it goes back to your tissue work and your cell work, and then you can create realistic models and real time, living models of the brain. It is a confluence, a convergence of all the different parties for a greater good and ultimately sustainable with big returns as well if you just think on the financial side. The third area that has me very excited is biomaterials. These are smart materials that you can deliver inside the body and be able to use the body's innate ability to do things to basically regenerate or induce, you know, tumor cell or things like that, with that, and you can actually integrate these sorts of materials with immune therapies. But there's other components. He entered into an affiliation agreement with UCLA to create the Terasaki Institute (formerly TFL) and began the process to locate the newly created Terasaki Institute in Westwood. And that tells you that these models are becoming sophisticated enough to begin to really, not only approach animal studies, but in some cases surpass animal studies in terms of predictive value. So, you know, for example, we have an ongoing program for breast cancer on a chip, including some of the breast cancers that are most difficult, , we're starting to explore metastasis on a chip. And these are just examples of the kinds of things you can do. But the timelines are very long. The Paul I. Terasaki Foundation. This history is captured in the interview with Stewart. Terasaki Institute - Home Terasaki Institute for Biomedical Innovation Announces Its New Facility Identifying and solving problems in new ways. Biomedical innovation is supported by rapid advancements in computing such as those pioneered by Jack Dongarra, recipient in 2022, of the ACM A.M. Turing Award, the Nobel of computing, for his foundational working in algorithms and software fueling the growth of high-performance computing (HPC). When applied to mice with finely tuned care, reverses signs of aging. I just was blown away by his approach to addressing some of the problems. We prefer to use the word physiological models on a chip. Jan 3 Don't miss your chance to be recognized for your groundbreaking research and contributions to the scientific community at the Terasaki Innovation Summit! SCI integrates technologies focused on the person in areas such as wound healing, brain computer interfaces (BCI) and neuro brain research, preventing pressure injury through electrical stimulation, VR /AR (mixed reality) and extended reality, AI and sensor technologies, robotics and exoskeletons for mobility, stem cells and regeneration. But if you're really serious about, taking it all the way to the impact, you can't stop at the lab experiment, you got to build products and to build products, you need to build companies. Terasaki Institute He's come up with technology for cellular agriculture, which is basically, it is meat, but it's without having to employ animals or what have you. You know, R&D rich innovation. Dr. Khademhosseini's interdisciplinary research has been recognized by over 60 major national and international awards. And there is not a value to do incremental work. And that was the transition into the food problem. One of the faculty that we recently hired at the Institute in the US recently came to us from Duke University, his name is Xiling Shen, and what he's done is quite incredible, because he actually takes tumor cells and forms them into these organoidsbeen able to then test different drugs, different chemotherapeutics on these tumor cells, and then see which drug works on which person's tumor. Pushed me to my academic career. But in virtually everything that we do, there is this opportunity to really use data sciences. And, if you think about the sort of conundrum of modern-day drug discovery, where essentially, we've never spent as much money on drug discovery, and we've never had fewer drugs that make it through the end of the gauntlet in terms of pipeline, it shows you that the way we're approaching drug discovery is not only inefficient, but possibly starting to be a diminishing return. Los Angeles, CA 90095-1487. So, you know, there's a lot of bioinspired work that me and others in the field are doing. All Rights Reserved. The Terasaki Institute for Biomedical Innovation (terasaki.org) is a non-profit research organization that invents and fosters practical solutions that restore or enhance the health of individuals . To illustrate I had a chat appearing with the non-profit IEEE TEMS (search for interviews with Stephen Ibaraki). And then you have to get usage and adoption, and then you have to scale it. We're super excited about all the growth and all the possibilities of the new Institute. He was always looking at connecting dots. K>. It means that you have to be very sharp all the time. Search for more papers by this author. But these could be actually, at the molecular level, you can have real interactions as well. The original founding premise of the Institute was for Dr. Terasaki, to continue his research that he wasn't able to finish off with his career at UCLA. So, what I'm hearing from you is, you got impact, you got big, and you can go right across the entire spectrum from idea to scaling, because you'll take in corporate partners, you have licensing models, that are business friendly; you'll incubate startups. These include IPhone / Mobile Compatible , SPF , and SSL by Default. .